The intraperitoneal delivery of the retroviral LXSN‐BRCA1 vector in BRCA‐1‐deficient ovarian cancer did not result in any clinical responses, possibly because of the vector's instability in the body.276. The gene discussed is BRCA1; the disease is ovarian carcinoma.